With the removal of Vioxx from the market and concerns about cardiovascular toxicity with other selective COX-2 inhibitors, patients are looking for safe alternatives, and manufacturers of other drugs are looking for additional market share. The COX-2 inhibitors first became popular because they have less upper GI toxicity than older less selective NSAIDs, at least in the short term, in patients not taking aspirin....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to
The Medical Letter on Drugs and Therapeutics, please
login or
register to view it online.
If you have already purchased this article, or have a subscription to
The Medical Letter on Drugs and Therapeutics, please
login or
register to view it online.
Information about the article:
Title: COX-2 Alternatives and GI Protection
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1195
Article Code: 1195b
Date: November 8, 2004
Volume: 46
Pages: 91-92